Redcare Pharmacy NV (RDC.DE)
EUR 139.9
(-3.38%)
EUR 139.9
(-3.38%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 399.83 Million EUR | -0.32% |
| 2022 | 401.1 Million EUR | 29.42% |
| 2021 | 309.93 Million EUR | 40.59% |
| 2020 | 220.45 Million EUR | 28.28% |
| 2019 | 171.86 Million EUR | 34.01% |
| 2018 | 128.24 Million EUR | 60.72% |
| 2017 | 79.79 Million EUR | 59.19% |
| 2016 | 50.12 Million EUR | 39.74% |
| 2015 | 35.87 Million EUR | 55.89% |
| 2014 | 23.01 Million EUR | 50.42% |
| 2013 | 15.29 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 120.32 Million EUR | -4.79% |
| 2024 Q2 | 117.24 Million EUR | -2.55% |
| 2023 Q1 | 110.68 Million EUR | 7.74% |
| 2023 Q3 | 111.52 Million EUR | 2.47% |
| 2023 Q2 | 108.84 Million EUR | -1.67% |
| 2023 Q4 | 126.38 Million EUR | 13.32% |
| 2023 FY | 399.83 Million EUR | -0.32% |
| 2022 Q3 | 96.62 Million EUR | -4.87% |
| 2022 Q4 | 102.73 Million EUR | 6.32% |
| 2022 FY | 401.1 Million EUR | 29.42% |
| 2022 Q1 | 100.17 Million EUR | 9.01% |
| 2022 Q2 | 101.57 Million EUR | 1.39% |
| 2021 Q1 | 75.28 Million EUR | 16.22% |
| 2021 Q2 | 71.49 Million EUR | -5.03% |
| 2021 Q3 | 71.26 Million EUR | -0.33% |
| 2021 FY | 309.93 Million EUR | 40.59% |
| 2021 Q4 | 91.89 Million EUR | 28.95% |
| 2020 Q3 | 53.66 Million EUR | 2.01% |
| 2020 FY | 220.45 Million EUR | 28.28% |
| 2020 Q4 | 64.77 Million EUR | 20.71% |
| 2020 Q2 | 52.61 Million EUR | 6.48% |
| 2020 Q1 | 49.4 Million EUR | 5.42% |
| 2019 Q2 | 39.74 Million EUR | -13.47% |
| 2019 FY | 171.86 Million EUR | 34.01% |
| 2019 Q1 | 45.93 Million EUR | 24.3% |
| 2019 Q4 | 46.86 Million EUR | 19.21% |
| 2019 Q3 | 39.31 Million EUR | -1.09% |
| 2018 Q4 | 36.95 Million EUR | 17.63% |
| 2018 FY | 128.24 Million EUR | 60.72% |
| 2018 Q1 | 31.1 Million EUR | 18.49% |
| 2018 Q2 | 28.77 Million EUR | -7.48% |
| 2018 Q3 | 31.41 Million EUR | 9.17% |
| 2017 Q1 | 18.87 Million EUR | 19.05% |
| 2017 Q2 | 16.76 Million EUR | -11.17% |
| 2017 Q4 | 26.24 Million EUR | 46.53% |
| 2017 Q3 | 17.91 Million EUR | 6.86% |
| 2017 FY | 79.79 Million EUR | 59.19% |
| 2016 Q4 | 15.85 Million EUR | 39.06% |
| 2016 Q3 | 11.39 Million EUR | 4.14% |
| 2016 Q2 | 10.94 Million EUR | -8.24% |
| 2016 Q1 | 11.92 Million EUR | 14.65% |
| 2016 FY | 50.12 Million EUR | 39.74% |
| 2015 Q1 | 7.92 Million EUR | 0.0% |
| 2015 FY | 35.87 Million EUR | 55.89% |
| 2015 Q2 | 7.92 Million EUR | 0.0% |
| 2015 Q4 | 10.4 Million EUR | 13.34% |
| 2015 Q3 | 9.18 Million EUR | 15.87% |
| 2014 FY | 23.01 Million EUR | 50.42% |
| 2013 FY | 15.29 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Newron Pharmaceuticals S.p.A. | 21.41 Million EUR | -1766.924% |